Adicet Bio
ACET

$1.53

4.79%

Market Cap: $126M

About: Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Employees: 143

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

8% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 26

12% less funds holding

Funds holding: 98 [Q1] → 86 (-12) [Q2]

18.08% less ownership

Funds ownership: 95.91% [Q1] → 77.83% (-18.08%) [Q2]

40% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 30

58% less capital invested

Capital invested by funds: $185M [Q1] → $77.4M (-$108M) [Q2]

84% less call options, than puts

Call options by funds: $7K | Put options by funds: $44K

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$4

161%

upside

Avg. target

$10.17

564%

upside

High target

$19

1,142%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

Jones Trading Soumit Roy 67% 1-year accuracy 4 / 6 met price target	161%upside $4	Buy Maintained	11 Sept 2024
Canaccord Genuity John Newman 67% 1-year accuracy 14 / 21 met price target	423%upside $8	Buy Maintained	11 Sept 2024
HC Wainwright & Co. Edward White 28% 1-year accuracy 32 / 116 met price target	554%upside $10	Buy Reiterated	14 Aug 2024
Canaccord Genuity John Newman 67% 1-year accuracy 14 / 21 met price target	1,142%upside $19	Buy Maintained	14 Aug 2024
HC Wainwright & Co. Edward White 28% 1-year accuracy 32 / 116 met price target	554%upside $10	Buy Reiterated	8 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ACET published over the past 30 days

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced ADI-001 clinical biomarker data from the Phase 1 GLEAN trial which further reinforces the potential of ADI-001 as a best-in-class allogeneic cell therapy for autoimmune diseases. Notably, ADI-001 demonstrated robust tissue trafficking resulting in high levels.

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue

UL Solutions Warns of Potentially Hazardous Communications Cable

NORTHBROOK, Ill.--(BUSINESS WIRE)--The following is a notification from UL Solutions that the communications cable that bears the serial numbers identified below may pose a potential fire hazard. The communications cable does not comply with the appropriate Safety Standards. Name of Product: CAT 5E 350MHZ CMR MODEL NUMBER W-CAT5E/CCU/1000/W UNSHIELDED TWISTED PAIR 24 AWG/4PAIR/1000FT Remedy: UL Solutions recommends that this product be removed from service. Identification on the Cable: E468535.

UL Solutions Warns of Potentially Hazardous Communications Cable

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 30, 2024. Three individuals were hired by Adicet in August 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 30,600 shares of Adicet's common stock with an exercise price of $1.46 pe.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference being held from September 9-11, 2024 in New York. Details of the event are as follows: Date: Tuesday, September 10, 2024 Time:.

Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. “We are pleased to welcome Dr. Klickstein to our Board of Directors,” said Chen Schor, President and Chief Executive Officer of Adicet Bio. “Dr. Klickstein's expertise in rheumatology.

Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2024. “We believe ADI-001 has best-in-class potential for autoimmune diseases and we are excited about the opportunity to expand ADI-001 clinical development beyond LN to include.

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates

Adicet Bio to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that company management will participate in two upcoming investor conferences in August. Details of the events are as follows: BTIG Virtual Biotechnology Conference, August 5-6, 2024 The Adicet Bio team will be available for one-on-one meetings during the conf.

Adicet Bio to Participate in Upcoming Investor Conferences

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on July 31, 2024. Four individuals were hired by Adicet in July 2024. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 70,400 shares of Adicet's common stock with an exercise price of $1.51 per sha.

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

Adicet (ACET) gains as the FDA grants the Fast Track designation to ADI-270 for the potential treatment of a form of kidney cancer. A phase I study for this indication is set to begin in 2024.

Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) who have been treated with an immune checkpoint inhibitor and a v.

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

See News Rankings